Welcome to our dedicated page for Selectquote SEC filings (Ticker: SLQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SelectQuote, Inc. (NYSE: SLQT) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed information about its insurance distribution and healthcare services businesses. These SEC filings cover topics such as financial results, segment performance, corporate governance matters and material financing agreements.
For SelectQuote, current reports on Form 8-K are particularly relevant for tracking key events. Recent 8-K filings describe the company’s entry into a new credit agreement that established a senior secured term loan and a senior secured revolving credit facility, with proceeds used in part to repay a prior credit facility and support working capital. Other 8-Ks report quarterly and annual financial results for the Senior, Healthcare Services and Life segments, including metrics such as Medicare Advantage policy approvals, SelectRx membership and life premium volumes. Additional 8-K disclosures cover matters submitted to stockholders at the annual meeting, including director elections, auditor ratification and advisory votes on executive compensation.
On this page, users can access SelectQuote’s 10-K annual reports and 10-Q quarterly reports, which provide comprehensive discussions of the company’s business model, segment results, risk factors and accounting policies. Filings related to credit agreements and amendments detail the terms, covenants and collateral securing the company’s debt. Proxy statements and associated filings explain the company’s governance structure and compensation programs.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points from lengthy filings, including revenue drivers in the Senior and Healthcare Services segments, pharmacy-related risks and debt structure changes. Users can also review insider transaction reports on Form 4, along with real-time updates from EDGAR, to monitor equity transactions by SelectQuote officers and directors.
SelectQuote, Inc. reported strategic growth in its healthcare and pharmacy businesses while managing leverage and shifting its distribution mix. Pharmacy revenue rose materially, increasing by $263.9 million (57%) in fiscal 2025 driven by a 31% increase in SelectRx members. Commission and other services revenue declined $59.1 million (7%), led by lower Senior commissions and a 4% decrease in approved policies. The company processed over 1.05 million assisted disclaimers with voice AI and saved over 4.7 million minutes of agent time through automation. SelectQuote reduced total debt to $385.1 million at June 30, 2025 (from $683.3 million prior year) after securitization and debt repayments, and held $37.1 million of cash and equivalents. The business remains concentrated: carriers owned by UHC, Aetna and Humana accounted for 37%, 15%, and 11% of revenue in 2025. The company emphasizes maximizing lifetime value (LTV) through AI-driven lead scoring, agent routing and post-sale retention efforts.
SelectQuote, Inc. (SLQT) filed an amendment to a prior Form 8-K to furnish a corrected press release reporting its financial results for the fourth quarter ended June 30, 2025. The press release was furnished as Exhibit 99.1 and is posted on the company’s Investor Relations website. The filing clarifies that the press release is being furnished (not "filed") for purposes of the federal securities laws and is incorporated by reference only as specified.
SelectQuote, Inc. disclosed that it reported financial results for the fourth quarter and the fiscal year ended June 30, 2025. The filing states that a related press release and an investor presentation are attached as Exhibits 99.1 and 99.2, and that those exhibits are furnished pursuant to Item 2.02 and are incorporated by reference. The company clarifies these exhibits are being furnished, not "filed", for purposes of Section 18 of the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings.
Form 4 shows President Robert Clay Grant’s latest equity activity at SelectQuote (SLQT) on 1–2 Aug 2025. Seven tranches of previously granted RSUs and price-vested units vested (transaction code M), delivering ≈631,089 common shares at $0 exercise cost. A day later, 204,163 shares were withheld at $1.74 to cover taxes (code F). Direct ownership after the transactions rose to 2,891,334 shares.
Grant continues to hold significant indirect stakes—1.24 M shares in a personal trust, 184.2 k shares across three children’s trusts, and 1.09 M shares via Haakon Capital—plus unvested derivative holdings. Table II records new equity compensation awards: 460 k time-based RSUs and 460 k price-vested RSUs granted on 1 Aug 2025 (code A), each convertible 1-for-1 into common stock and subject to multi-year vesting/performance hurdles. Remaining unvested derivative balance totals several hundred-thousand units.
FAQ
What is the current stock price of Selectquote (SLQT)?
What is the market cap of Selectquote (SLQT)?
